cytosine

(redirected from cytosine arabinoside)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to cytosine arabinoside: Daunorubicin
  • noun

Synonyms for cytosine

a base found in DNA and RNA and derived from pyrimidine

References in periodicals archive ?
Among these, butyl p-tolyl sulfide, 6-methyl-4-chromanone and butylated hydroxyanisole appear to be the most interesting and exhibit an antiproliferative effect comparable to that of other antitumor compounds, including cisplatin, chromomycin, cytosine arabinoside and 5-fluorouracil.
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a Cancer and Leukemia Group B study Blooel 1982;60:454-462.
The researchers found a profound loss of hair follicles in rats treated with cytosine arabinoside alone, but no follicle reduction among those receiving both drugs.
The patient was admitted to the hospital and underwent induction chemotherapy with cytosine arabinoside (Ara-C) (100 mg/[m.
Since the retroperitoneal mass persisted in follow-up abdominal CT, a new chemotherapy regimen containing fludarabine, cytosine arabinoside, and idarubicin was started.
The poster (Abstract #7051) entitled "A double blind placebo-controlled randomized phase III study of high-dose continuous infusion cytosine arabinoside (araC) with or without VNP40101M in patients with first relapse of AML" will be presented at McCormick Place, South Hall A1, Board 38E from 8:00 a.
Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and Daunorubicin.
The FDA approval followed a priority review and was based on 12-month data from a large head-to-head study comparing Gleevec with a combination of interferon-alpha and cytosine arabinoside (IFN/Ara-C), a traditional treatment for CML.
After immunohistochemical examination the patient was diagnosed with AML MO, and classic 7+3 induction chemotherapy regimen involving cytosine arabinoside and idarubicin combination protocol was initiated.
20 /PRNewswire/ -- Xanthus Life Sciences today announced the commencement of a Phase 2 study of Xanafide(TM) (amonafide malate) in combination with cytosine arabinoside (ara-C) for the treatment of patients with secondary acute myeloid leukemia (AML).